AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

Orphan drug designation (25 Aug 2010): EU/3/10/769 (11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1. 1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene, Voisin Consulting SARL).

Chemical Business Newsbase

| August 27, 2010 | COPYRIGHT 2000 Elsevier Engineering Information, Inc. (Hide copyright information)Copyright

On 27 Aug 2010, the European Commission (EC) announced decision number C(2010)5967 of 25 Aug 2010, the approval of EU orphan drug designation EU/3/10/769. The active ingredient is 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene …

Related articles from newspapers, magazines, journals, and more
Orphan drug designation: EU/3/10/761 (3-(6-(1-(2,2-difluorobenzo [d] [1,3]...
News wire article from: Chemical Business Newsbase August 4, 2010 700+ words
Orphan drug designation (25 Aug 2010): EU/3/10/767...
News wire article from: Chemical Business Newsbase August 27, 2010 700+ words
Orphan drug designation (25 Aug 2010): EU/3/10/768...
News wire article from: Chemical Business Newsbase August 27, 2010 700+ words
Orphan drug designation (29 Jan 2010): EU/3/09/712 (Recombinant kallikrein...
News wire article from: Chemical Business Newsbase February 2, 2010 700+ words
Orphan drug designation (15 May 2009): EU/3/09/636 (Dexamethasone phosphate...
News wire article from: Chemical Business Newsbase May 20, 2009 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily